AZD-9833

2222844-89-3

476.51

DMSO : 100 mg/mL (209.86 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble)

Others

AZD-9833 is a potent and orally active estrogen receptor (ER) antagonist. AZD-9833 is used for the study of ER⁺ HER2-advanced breast cancer^[1]. IC50 & Target: IC50: estrogen receptor (ER)^[1] In Vitro: AZD-9833 is extracted from patent US20180111931A1, example 17^[1]. In Vivo: AZD-9833 (oral administration; 0.2-50 mg/kg; 20 days) exhibits anti-tumour efficacy as a dose-dependent manner in human parental MCF7 mice xenograft^[1].
AZD-9833 (oral administration; 0.8-40 mg/kg; 30 days) decreases tumor growth as a dose-dependent manner. It gives almost complete tumour growth inhibition at the doses >10 mg/kg in mice^[1].